drugset / Trial / NCT04633564
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
Timeline
- Start
- 2017-01-21
- Primary completion
- 2019-06-05
- Completion
- 2019-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | MYL-1402O | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | Intravenous |